The antiviral drug tecovirimat (Tpoxx) didn't accelerate lesion clearance in adults and children with clade 1 mpox ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA). Vi ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long awaited new treatment for early ...

The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. Advertisement Article ...

Anavex could secure conditional approval for blarcamesine, though longer trials may be needed. Check out why AVXL stock is a ...

The European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab in combination with platinum-based chemotherapy for the first-line ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.